NYSE - Delayed Quote • USD
AbbVie Inc. (ABBV)
At close: May 14 at 4:00 PM EDT
Pre-Market: 6:16 AM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
54,403,000.00
54,318,000.00
58,054,000.00
56,197,000.00
45,804,000.00
Cost of Revenue
20,523,000.00
20,415,000.00
17,414,000.00
17,446,000.00
15,387,000.00
Gross Profit
33,880,000.00
33,903,000.00
40,640,000.00
38,751,000.00
30,417,000.00
Operating Expense
20,301,000.00
20,368,000.00
21,826,000.00
19,703,000.00
17,678,000.00
Operating Income
13,579,000.00
13,535,000.00
18,814,000.00
19,048,000.00
12,739,000.00
Net Non Operating Interest Income Expense
-1,683,000.00
-1,684,000.00
-2,044,000.00
-2,384,000.00
-2,280,000.00
Other Income Expense
-4,366,000.00
-5,601,000.00
-3,293,000.00
-3,675,000.00
-7,061,000.00
Pretax Income
7,530,000.00
6,250,000.00
13,477,000.00
12,989,000.00
3,398,000.00
Tax Provision
1,526,000.00
1,377,000.00
1,632,000.00
1,440,000.00
-1,224,000.00
Net Income Common Stockholders
5,951,000.00
4,820,000.00
11,782,000.00
11,468,000.00
4,556,000.00
Diluted NI Available to Com Stockholders
5,951,000.00
4,820,000.00
11,782,000.00
11,468,000.00
4,556,000.00
Basic EPS
3.37
2.75
6.65
6.48
2.73
Diluted EPS
3.36
2.72
6.63
6.45
2.72
Basic Average Shares
1,767,750.00
1,765,940.73
1,771,000.00
1,770,000.00
1,667,000.00
Diluted Average Shares
1,772,250.00
1,773,000.00
1,778,000.00
1,777,000.00
1,673,000.00
Total Operating Income as Reported
12,787,000.00
12,757,000.00
18,117,000.00
17,924,000.00
11,363,000.00
Total Expenses
40,824,000.00
40,783,000.00
39,240,000.00
37,149,000.00
33,065,000.00
Net Income from Continuing & Discontinued Operation
5,993,000.00
4,863,000.00
11,836,000.00
11,542,000.00
4,616,000.00
Normalized Income
6,716,190.97
5,583,720.00
12,578,755.00
12,586,575.00
5,672,310.00
Interest Income
648,000.00
540,000.00
186,000.00
39,000.00
174,000.00
Interest Expense
2,331,000.00
2,224,000.00
2,230,000.00
2,423,000.00
2,454,000.00
Net Interest Income
-1,683,000.00
-1,684,000.00
-2,044,000.00
-2,384,000.00
-2,280,000.00
EBIT
9,861,000.00
8,474,000.00
15,707,000.00
15,412,000.00
5,852,000.00
EBITDA
18,506,000.00
17,172,000.00
24,174,000.00
23,933,000.00
12,323,000.00
Reconciled Cost of Revenue
20,523,000.00
20,415,000.00
17,414,000.00
17,446,000.00
15,387,000.00
Reconciled Depreciation
8,645,000.00
8,698,000.00
8,467,000.00
8,521,000.00
6,471,000.00
Net Income from Continuing Operation Net Minority Interest
5,993,000.00
4,863,000.00
11,836,000.00
11,542,000.00
4,616,000.00
Total Unusual Items Excluding Goodwill
-907,000.00
-924,000.00
-845,000.00
-1,175,000.00
-1,447,000.00
Total Unusual Items
-907,000.00
-924,000.00
-845,000.00
-1,175,000.00
-1,447,000.00
Normalized EBITDA
19,413,000.00
18,096,000.00
25,019,000.00
25,108,000.00
13,770,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-183,809.03
-203,280.00
-102,245.00
-130,425.00
-390,690.00
12/31/2020 - 1/2/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
JNJ Johnson & Johnson
151.38
+0.11%
MRK Merck & Co., Inc.
128.66
-0.49%
BMY Bristol-Myers Squibb Company
44.71
-0.78%
AMGN Amgen Inc.
311.41
+0.96%
PFE Pfizer Inc.
28.38
-0.21%
LLY Eli Lilly and Company
763.98
+0.83%
GILD Gilead Sciences, Inc.
67.65
+0.16%
AZN AstraZeneca PLC
77.04
-0.50%
NVS Novartis AG
103.31
+1.03%
GSK GSK plc
45.66
+1.08%